Reimbursed Care Access in Fiji

Currently classified as a strictly controlled substance under Fiji’s Illicit Drugs Control Act 2004 with no authorised medical use or routine clinical prescribing outside of formally approved clinical research. Attempts to obtain psilocybin for treatment outside an authorised trial would fall afoul of the national illicit‑drugs scheduling and criminal provisions. #.

Currently classified as a strictly controlled substance under Fiji’s Illicit Drugs Control Act 2004, with no authorised medical use or reimbursement pathway outside of approved clinical research. Access is limited to regulated research if (and where) special approvals are granted. #.

Esketamine (marketed internationally as Spravato) is not documented as an authorised, reimbursed product within Fiji’s public health procurement or national reimbursement mechanisms, and there is no publicly available evidence of national regulatory registration or government reimbursement for esketamine in Fiji. Ketamine (the racemate) is a WHO‑recognised essential anaesthetic and is used in clinical practice globally as an anaesthetic and analgesic; Fiji’s national medicines and health system rely on conventional anaesthetic medicines for surgical and emergency care, which supports licensed clinical use of ketamine as an anaesthetic agent rather than as an antidepressant with a reimbursement pathway. # #.

Ketamine is an established essential medicine for anaesthesia and emergency analgesia and is included on the WHO Model List of Essential Medicines (documenting global clinical acceptance for anaesthetic use). In Fiji, conventional health‑system use of ketamine for anaesthesia and acute medical indications is consistent with national clinical practice and permitted under the medicines/poisons regulatory framework; such use is provided within hospitals and clinical settings rather than as a reimbursed, structured psychedelic psychotherapeutic service. There is no evidence that ketamine is covered or reimbursed by a specific national public programme when used off‑label for psychiatric indications (e.g., treatment‑resistant depression) — off‑label psychiatric ketamine infusions would be exceptional, delivered in private clinical settings if at all, and would lack a formal national reimbursement pathway. For the statute establishing illicit/controlled drugs and medicines governance, see the Illicit Drugs Control Act 2004. # #.

Currently classified as a strictly controlled substance under Fiji’s Illicit Drugs Control Act 2004 with no authorised medical use outside of approved clinical research; possession, importation and supply are criminalised. #.

Currently classified as a strictly controlled substance under Fiji’s Illicit Drugs Control Act 2004 with no authorised medical use outside of approved clinical research. There are no public reimbursement or licensed therapeutic frameworks for 5‑MeO‑DMT in Fiji. #.

Currently classified as a strictly controlled substance under Fiji’s Illicit Drugs Control Act 2004 with no authorised medical use, treatment programmes or reimbursement outside of approved clinical research. There is no regulatory framework in Fiji that supports ibogaine clinics or licensed therapeutic use. #.

Because DMT (a principal psychoactive constituent of ayahuasca) is a scheduled illicit substance under Fiji law, ayahuasca preparations intended for human consumption are treated as containing a prohibited substance; there is no authorised traditional‑use exemption or medical reimbursement pathway and use outside regulated research or authorised import/export channels would be unlawful. #.

Currently classified as a strictly controlled substance under Fiji’s Illicit Drugs Control Act 2004 with no authorised medical use or reimbursement outside of approved clinical research. Peyote or other mescaline‑containing cacti do not have a recognised legal exemption for traditional or religious use under current Fiji law. #.

Currently classified as a strictly controlled substance (as part of broader scheduled psychotropic/novel psychoactive substance control measures) under Fiji’s Illicit Drugs Control Act 2004 with no authorised medical use or reimbursement outside tightly regulated clinical trials. Possession and supply are criminal offences. #.